Efficacy and safety of glucagon-like peptide-1 (GLP-1) agonists in pediatric obesity: A systematic review and meta-analysis

Ghassan A. Sukkar; Mumen H. Halabi; Yousef H. Faden

doi:10.4103/sjg.sjg_455_25

March 18, 2026Saudi Journal of GastroenterologyOpen Access

Efficacy and safety of glucagon-like peptide-1 (GLP-1) agonists in pediatric obesity: A systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the efficacy and safety of glucagon-like peptide-1 receptor agonists in treating pediatric obesity.
Conducted a systematic review and meta-analysis of existing studies.
Focused on anthropometric measures and cardiometabolic outcomes.
Assessed safety profiles of glucagon-like peptide-1 receptor agonists.
GLP-1 receptor agonists significantly improve anthropometric measures in pediatric obesity.
Selected cardiometabolic outcomes also show improvement with these treatments.
Overall, the safety profile of GLP-1 receptor agonists is favorable.

Implication

Systematic review on GLP-1 agonists improves cardiometabolic outcomes in pediatric obesity, suggesting beneficial effects.

Abstract

GLP-1 RAs improve anthropometric and selected cardiometabolic outcomes in pediatric obesity with an overall favorable safety profile. Larger, high-quality trials are needed to confirm these findings.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sukkar et al. (2026) studied this question.

synapsesocial.com/papers/69be371c6e48c4981c676885 https://doi.org/10.4103/sjg.sjg_455_25

View Full Paper

Ask AI

Bookmark

Share

Efficacy and safety of glucagon-like peptide-1 (GLP-1) agonists in pediatric obesity: A systematic review and meta-analysis

Key Points

Implication

Abstract

Discussion

Cite This Study

Efficacy and safety of glucagon-like peptide-1 (GLP-1) agonists in pediatric obesity: A systematic review and meta-analysis

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading